Abstracts tagged "Quality of life and vasculitis"

Abstract Number: 2973 • 2016 ACR/ARHP Annual Meeting
A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Matthew Gray¹, Delesha M. Carpenter², Lorie L. Geryk³, Courtney A. Roberts⁴, Joshua M. Thorpe⁵, Tao Jiang⁵, Susan L Hogan⁶ and Carolyn T. Thorpe⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Asheville, NC, ³Division of Pharmaceutical Outcomes and Policy, University of North Carolina, Chapel Hill, NC, ⁴Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ⁵School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, ⁶UNC Kidney Center, Chapel Hill, NC
Background/Purpose: Serving as an informal caregiver to a family member or friend with a chronic illness is associated with stress, reduced health status, and financial…
Abstract Number: 3046 • 2015 ACR/ARHP Annual Meeting
Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease
Fatma Alibaz-Oner¹, Belgin Aldag², Mustafa Aldag³, Ali Ugur Unal⁴, Tayfur Toptas⁵, Tülin Ergun⁶ and Haner Direskeneli⁴, ¹Department Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ³Dr.Siyami Ersek Cardiovascular Surgery Hospital,, Istanbul, Turkey, ⁴Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁵Hematology, Marmara University, Istanbul, Turkey, ⁶Dermatology, Marmara University Faculty of Medicine, Dermatology, Istanbul, Turkey
Background/Purpose: Vascular involvement is seen in up to 40% of the patients with Behcet's disease (BD), with lower extremity deep vein thrombosis (DVT) as the most…
Abstract Number: 1778 • 2014 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life
Grégory Pugnet^1,2, Christian Pagnoux³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaître⁶, Pascal Cohen¹, Francois Maurier⁷, Olivier Decaux⁸, Jacques Ninet⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puéchal¹, Pierre-Louis Carron¹⁴, Pierre-Yves Hatron¹⁵, Nicolas Limal¹⁶, Mohamed Hamidou¹⁷, Eric Daugas¹⁸, Thomas Papo¹⁹, Bernard Bonnotte²⁰, Alfred Mahr²¹, Benjamin Terrier¹, Philippe Ravaud²², Luc Mouthon¹ and Loïc Guillevin¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Toulouse University Hospital, Internal Medicine Department, Toulouse, France, ³Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal Medicine, CH, Valenciennes, France, ¹²Internal Medicine, Hôpital de Niort, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, ¹⁵CHU Lille, Lille, France, ¹⁶Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, ¹⁷CHU Hôtel Dieu, Nantes, Nantes, France, ¹⁸Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, ¹⁹Internal Medicine, Bichat Hospital, Paris, Paris, France, ²⁰Dijon University Hospital, INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, ²¹Internal Medicine, Hospital Saint-Louis, University Paris 7, Paris, France, ²²Epidemiology, AP-HP Cochin Hospital, Paris, France
Background/Purpose A key goal in the management of ANCA-Associated Vasculitis (AAV) is to improve and preserve health-related quality of life (HRQOL). Several studies have found that…
Abstract Number: 1525 • 2012 ACR/ARHP Annual Meeting
Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV)
Neil Basu¹, Andrew McClean², Raashid A. Luqmani³, Lorraine Harper², Oliver Flossmann⁴, David Jayne⁵, Mark Little⁶, Esther N. Amft⁷, Neeraj Dhaun⁸, John McLaren⁹, Vinod Kumar¹⁰, Lars Erwig¹¹, Gareth T. Jones¹, David M. Reid¹² and Gary J. Macfarlane¹, ¹Musculoskeletal Research Collaboration (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²Nephrology, University of Birmingham, Birmingham, United Kingdom, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶Clinical Medicine, Trinity College Dublin, Dublin, Ireland, ⁷Rheumatic Diseases Unit, Western General Hospital, Edinburgh, United Kingdom, ⁸Nephrology, Edinburgh Royal Infirmary, Edinburgh, United Kingdom, ⁹Fife Rheumatic Diseases Unit, NHS Fife, Whyteman's Brae Hospital, Kirkcaldy, United Kingdom, ¹⁰Rheumatology, Ninewells Hospital, Dundee, United Kingdom, ¹¹Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom, ¹²Musculoskeletal Research Collaboration (Medicine & Therapeutics), University of Aberdeen, Aberdeen, United Kingdom
Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV) Background/Purpose : Patients with ANCA associated vasculitis (AAV) report significantly reduced quality of life (QOL),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].